← Back to Search

Alcohol Deterrent

Copper gluconate for Glioblastoma

Phase 2

Waitlist Available

Led By George Bobustuc, MD

Research Sponsored by Aurora Health Care

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 and 2 years

Awards & highlights

Study Summary

This trial is testing if adding Disulfiram + Copper to standard Temozolomide treatment can improve outcomes for patients with unmethylated Glioblastoma.

Eligible Conditions

Glioblastoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 and 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 and 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

6 Months Progression Free Survival (PFS)

Overall Survival

Secondary outcome measures

Quality of Life (QOL)

Trial Design

1Treatment groups

Experimental Treatment

Group I: DSF-Cu with temozolomide and radiationExperimental Treatment3 Interventions

Disulfiram (DSF; oral) / copper gluconate (Cu; oral) dosed at 125 mg / 2 mg, twice daily. Temozolomide will be administered following the standard Stupp protocol at a dose of 75 mg/m2 for 42 days with concurrent radiation therapy. Temozolomide maintenance dose will be 150 mg/m2 once daily on Days 1-5 of every 28-day cycle while DSF-Cu is continued twice daily, as tolerated, for the duration of the Temozolomide adjuvant treatment. Patients demonstrating continued benefit from the adjuvant temozolomide after 6 cycles can continue treatment to a maximum of 12 cycles

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Disulfiram

FDA approved

Copper gluconate

2013

Completed Early Phase 1

~30

Temozolomide

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Aurora Health CareLead Sponsor

42 Previous Clinical Trials

16,017 Total Patients Enrolled

George Bobustuc, MDPrincipal InvestigatorAurora Health Care

Asadullah Khan, MDPrincipal InvestigatorAurora Health Care

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Federal Drug Administration authorized Temozolomide for consumer use?

"With only preliminary data backing its safety, temozolomide was assigned a score of 2. There is no existing evidence indicating that it can effectively treat any form of cancer."

Answered by AI

Is enrollment for this scientific experiment still open?

"As per clinicaltrials.gov, this experiment is no longer recruiting patients - the original posting was on March 28th 2018 and last edited 9/8/2021. Although not enrolling any more candidates, 654 other studies are currently looking for participants to join their trials."

Answered by AI

To what end is Temozolomide customarily employed?

"Nitrosourea therapy is typically treated with temozolomide. This drug has demonstrated success at mitigating the severity of advanced directives, refractory cases of mycosis fungoides, and neuroblastoma that has not responded to other treatments."

Answered by AI

Has Temozolomide been utilized in prior research endeavors?

"Presently, 212 distinct studies are underway for Temozolomide. Of these trials, 24 have entered the final phase of testing before approval. The majority of these tests are conducted in Seoul and Songpa; yet there remain 4784 different research sites actively studying this drug."

Answered by AI

Is this a groundbreaking or unprecedented trial?

"Since its initial trial in 2002, sponsored by Schering-Plough and involving 60 participants, Temozolomide has been subject to visible research attention. In fact, there are currently 212 active trials spanning 36 countries and 944 cities globally."

Answered by AI

How many participants are being monitored for this clinical experiment?

"Currently, this research is not accepting any new patients. Initially posted on March 28th 2018 and last edited on September 8th 2021, those interested in other studies should know that 442 trials for glioblastoma and 212 examinations utilizing Temozolomide are actively recruiting participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

2018. "Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03363659.